EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model

Manuel E Lopez iD, Daniel Wendt, Roger Lawrence, Kerui Gong, Hoonsan Ong, Bryan Yip, Joseph Chen, Linley Mangini, Britta Handyside, Alexander Giaramita, Aashish Lamichhane, Melanie Lo und 15 weitere

PLOS ONE · 03.01.2025 · 20 (1) · e0315005

DOI: 10.1371/journal.pone.0315005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 03.01.2025. Verfasst von Manuel E Lopez und 26 weiteren Autor:innen. Beteiligte Einrichtung: BioMarin Pharmaceutical Inc., Novato, CA, United States of America. Hauptthemen laut MEDLINE: Disease Models, Animal, Sandhoff Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Allievex Corporation, BioMarin Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The GM2 gangliosidoses, Tay-Sachs disease and Sandhoff disease, are devastating neurodegenerative disorders caused by β-hexosaminidase A (HexA) deficiency. In the Sandhoff disease mouse model, rescue potential was severely reduced when HexA was introduced after disease onset. Here, we assess the effect of recombinant HexA and HexD3, a newly engineered mimetic of HexA optimized for the treatment of Tay-Sachs disease and Sandhoff disease. Enzyme replacement therapy was administered by repeat intracerebroventricular injections in Sandhoff disease model mice with dosing beginning before and after signs of neurodegeneration. As previously observed, HexA effectively increased the lifespan of Sandhoff disease mice by 3.5-fold only when treatment was started before onset of neurodegeneration. In contrast, HexD3 halted motor decline and ameliorated late-stage disease severity even when dosing began late, after neurodegeneration onset. Additionally, HexD3 had advantages over HexA in enzyme stability, distribution potential, and homodimer activity. Overall, our data indicate that advanced therapeutics may widen the treatment window for neurodegenerative disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Disease Models, AnimalSandhoff DiseaseAnimalsMiceInjections, IntraventricularHexosaminidase AEnzyme Replacement TherapyRecombinant ProteinsHumansG(M2) GangliosideTay-Sachs Disease

Substanzen

Hexosaminidase ARecombinant ProteinsG(M2) Ganglioside

Autor:innen und Institutionen

  • BioMarin Pharmaceutical Inc., Novato, CA, United States of America.

ORCID-Profile: Manuel E Lopez

Förderung

  • Allievex Corporation
  • BioMarin Pharmaceutical

Zitieren

APA

Lopez, M. E., Wendt, D., Lawrence, R., Gong, K., Ong, H., Yip, B., Chen, J., Mangini, L., Handyside, B., Giaramita, A., Lamichhane, A., Lo, M., Agrawal, V., Van Vleet, J., Abolhesn, A., Felix, J. B., Villalpando, I., Bhat, V., De Angelis, R., …, & Aoyagi-Scharber, M. (2025). Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model. PLOS ONE, 20(1), e0315005. https://doi.org/10.1371/journal.pone.0315005

Vancouver

Lopez ME, Wendt D, Lawrence R, Gong K, Ong H, Yip B, et al. Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model. PLOS ONE. 2025;20(1):e0315005. doi:10.1371/journal.pone.0315005

BibTeX
@article{Lopez2025,
  author = {Lopez, Manuel E and Wendt, Daniel and Lawrence, Roger and Gong, Kerui and Ong, Hoonsan and Yip, Bryan and Chen, Joseph and Mangini, Linley and Handyside, Britta and Giaramita, Alexander and Lamichhane, Aashish and Lo, Melanie and Agrawal, Vishal and Van Vleet, Jeremy and Abolhesn, Amanda and Felix, Jessica B and Villalpando, Isaac and Bhat, Vikas and De Angelis, Rolando and Ru, Yuanbin and Khan, Ayesha and Fong, Sylvia and Christianson, Terri and Bullens, Sherry and Crawford, Brett E and Bunting, Stuart and Aoyagi-Scharber, Mika},
  title = {Intracerebroventricular administration of a modified hexosaminidase ameliorates late-stage neurodegeneration in a GM2 mouse model},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {1},
  pages = {e0315005},
  doi = {10.1371/journal.pone.0315005}
}
Kostenlos starten →